Asparaginase unveils glutamine-addicted AML

Blood

Volumn 122, Issue 20, 2013, Pages 3398-3400

  Samudio, Ismael ^a   Konopleva, Marina ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CD34 ANTIGEN; CITRIC ACID; GLUTAMATE AMMONIA LIGASE; GLUTAMINE; LEUCINE; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; POLYPEPTIDE; S6 KINASE; TRANSFER RNA;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; AUTOPHAGY; CANCER CELL; CELL LEVEL; CELL SURFACE; CELL VIABILITY; DEAMINATION; ENZYME ACTIVITY; HUMAN; IMMUNE DEFICIENCY; LEUKEMIA CELL; LEUKEMIA CELL LINE; LYSOSOME; PANCREATITIS; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN DEPLETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; STEM CELL; SURVIVAL; THROMBOSIS; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84888231872     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-526392     Document Type: Review

References (10)

1. Willems L, Jacque N, Jacquel A, et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood. 2013;122(20):3521-3532.
2. Nachman J, Sather HN, Gaynon PS, Lukens JN, Wolff L, Trigg ME. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group. J Clin Oncol. 1997;15(6):2222-2230.
3. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(28):7161-7167.
4. Faderl S, Thomas DA, O'Brien S, et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymph Myeloma Leuk. 2011;11(1):54-59.
5. Buaboonnam J, Cao X, Pauley JL, et al. Sequential administration of methotrexate and asparaginase in relapsed or refractory pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2013;60(7):1161-1164.
6. Avramis VI. Asparaginases: biochemical pharmacology and modes of drug resistance. Anticancer Res. 2012;32(7):2423-2437.
7. Ramya LN, Doble M, Rekha VP, Pulicherla KK. L-Asparaginase as potent anti-leukemic agent and its significance of having reduced glutaminase side activity for better treatment of acute lymphoblastic leukaemia. Appl Biochem Biotechnol. 2012;167(8):2144-2159.
8. Hensley CT, Wasti AT, Deberardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Invest. 2013;123(9):3678-3684.
9. Nicklin P, Bergman P, Zhang B, et al. Bidirectional transport of amino acids regulates mTOR and autophagy. Cell. 2009;136(3):521-534.
10. Ehsanipour EA, Sheng X, Behan JW, et al. Adipocytes cause leukemia cell resistance to L-asparaginase via release of glutamine. Cancer Res. 2013;73(10):2998-3006.